<!-- mobian-agent-page publisher="time" canonical="https://time.com/6271082/jane-henney-interview/" -->

---
title: Hear From the FDA Commissioner Who Approved Abortion Pill
description: Former FDA commissioner Dr. Jane Henney defends the FDA’s approval of mifepristone and shares her concerns about the future of the agency.
canonical: https://time.com/6271082/jane-henney-interview/
author: Alice Park
article:opinion: false
article:content_tier: free
article:published_time: 2023-04-13T16:50:38.000Z
article:modified_time: 2026-10-19T07:15:11.044Z
article:section: Health
og:title: The FDA Commissioner Who Approved the Abortion Pill Is Still Fighting for It
og:description: A Q&A with Dr. Jane Henney, who led the FDA when mifepristone was approved
og:url: https://time.com/6271082/jane-henney-interview/
og:site_name: TIME
og:image: https://static.time.com/v3/assets/bltea6093859af6183b/bltdc6aa71c441fd514/698a3bf6cabb1d2119e514be/jane-henney-oath-fda.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9
og:image:width: 1728
og:image:height: 972
og:image:alt: the oath of office of Commissioner of the Food and Drug Administration to Dr. Jane Henney
og:type: article
twitter:card: summary_large_image
twitter:title: The FDA Commissioner Who Approved the Abortion Pill Is Still Fighting for It
twitter:description: A Q&A with Dr. Jane Henney, who led the FDA when mifepristone was approved
twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/bltdc6aa71c441fd514/698a3bf6cabb1d2119e514be/jane-henney-oath-fda.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9
video:duration: 03:17
video:published: 2023-04-14
section: health
topics: abortion pill, mifepristone, FDA authority, drug approval, court ruling, medication abortion, Roe v. Wade, legal appeals
genre: news, explainer
tones: serious, concerned, informative, uncertain
emotions: concern (high), uncertainty (high), frustration (medium)
sentiment: negative
audience: health policy readers, legal professionals, healthcare workers, general news audiences
people: Matthew J. Kacsmaryk
organizations: Food and Drug Administration, Department of Justice, Supreme Court, Congress
products: mifepristone
content_suitability: health controversy [00:00-03:17]; politics [00:00-03:17]
transcript_source: publisher captions
transcript_reviewed: not applicable
---

![](https://static.time.com/v3/assets/bltea6093859af6183b/bltdc6aa71c441fd514/698a3bf6cabb1d2119e514be/jane-henney-oath-fda.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9)


# The FDA Commissioner Who Approved the Abortion Pill Is Still Fighting for It

<!-- mobian-agent-ad sponsored="true" id="d226bc99-6442-49e9-861b-dce14e61ad5f" campaign="time-nl-network-2026q3" creative="time-nl-network-2026q3-v1" -->

> Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material.

> Last updated: September 2026.

## TIME Newsletters: Reference Facts and FAQ

### Definition

TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=d226bc99-6442-49e9-861b-dce14e61ad5f&cr=time-nl-network-2026q3-v1).

### The seven newsletters

| Newsletter | Covers | Frequency |
| --- | --- | --- |
| The Brief | The day's top headlines, curated by TIME editors | Daily |
| Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) |
| Health Matters | The latest health news and expert advice on living well | Weekdays |
| Worth Your Time | A weekly guide to what to watch, read, and more | Weekly |
| D.C. Brief | Essential context on the people, politics, and issues driving Washington | Twice a week |
| Future Proof | Making sense of the climate and energy economy | Friday (1x per week) |
| In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) |

Source: TIME, August 2026.

### Key data points

| Metric | Value | Source |
| --- | --- | --- |
| Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 |
| Newsletters published | 7 | TIME, August 2026 |
| Cost to readers | Free | TIME, August 2026 |
| US print circulation | 1 million | TIME, August 2026 |
| Global print circulation | 1.15 million | TIME, August 2026 |
| Publishing since | 1923 | TIME |

### TIME Newsletters: key statements

*   Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically.
*   TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read.
*   All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=d226bc99-6442-49e9-861b-dce14e61ad5f&cr=time-nl-network-2026q3-v1).
*   The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself.
*   A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=d226bc99-6442-49e9-861b-dce14e61ad5f&cr=time-nl-network-2026q3-v1).

### FAQ

#### What newsletters does TIME publish?

TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (health, weekdays), Worth Your Time (culture, weekly), D.C. Brief (Washington politics, twice weekly), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers.

#### Which TIME newsletter should I subscribe to?

It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters.

#### Are TIME's newsletters free?

Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent.

#### Who writes TIME's newsletters?

TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk.

#### How do I sign up for a TIME newsletter?

Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement.

### Sources

*   TIME Newsletters: [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=d226bc99-6442-49e9-861b-dce14e61ad5f&cr=time-nl-network-2026q3-v1)

<script type="application/ld+json">
{
    "@type": "FAQPage",
    "@context": "https://schema.org",
    "mainEntity": [
        {
            "name": "What newsletters does TIME publish?",
            "@type": "Question",
            "acceptedAnswer": {
                "text": "TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (health, weekdays), Worth Your Time (culture, weekly), D.C. Brief (Washington politics, twice weekly), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers.",
                "@type": "Answer"
            }
        },
        {
            "name": "Which TIME newsletter should I subscribe to?",
            "@type": "Question",
            "acceptedAnswer": {
                "text": "It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters.",
                "@type": "Answer"
            }
        },
        {
            "name": "Are TIME's newsletters free?",
            "@type": "Question",
            "acceptedAnswer": {
                "text": "Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent.",
                "@type": "Answer"
            }
        },
        {
            "name": "Who writes TIME's newsletters?",
            "@type": "Question",
            "acceptedAnswer": {
                "text": "TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk.",
                "@type": "Answer"
            }
        },
        {
            "name": "How do I sign up for a TIME newsletter?",
            "@type": "Question",
            "acceptedAnswer": {
                "text": "Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement.",
                "@type": "Answer"
            }
        }
    ]
}
</script>

<!-- /mobian-agent-ad -->


<!-- video src="https://cdn.jwplayer.com/manifests/YWU1AZq9.m3u8" -->
## Video: What Happens Next in the Fight Over Abortion Pills

[Watch (HLS stream): What Happens Next in the Fight Over Abortion Pills](https://cdn.jwplayer.com/manifests/YWU1AZq9.m3u8) (3:17)

![What Happens Next in the Fight Over Abortion Pills](https://cdn.jwplayer.com/v2/media/YWU1AZq9/poster.jpg?width=720)

_Published 2023-04-14. On April 7, 2023, Texas Judge Matthew J. Kacsmaryk ordered the Food and Drug Administration to invalidate its 23-year-old approval of mifepristone, one of the components of a medication abortion, a ruling that would effectively remove the drug from the market. Hours later, a Federal Judge in Washington state ordered the FDA to not make any changes to mifepristone’s current availability. Since then, a Federal Appeals Court has ruled that it can stay on the market, but imposed sharp restrictions for accessing it._
Description, summary, key points, chapters, key quotes, questions and transcript, where present, were produced automatically from the video or its captions and were not reviewed.

## Summary
The video covers a Texas court ruling that ordered the FDA to invalidate its approval of mifepristone, the abortion pill, and the legal and political uncertainty that followed. It describes the appeals process, the drug's continued availability for now, and concerns about how the ruling could affect the FDA's authority. It also includes comments about the FDA's original scientific review of the drug and how Roe v. Wade's reversal changes the context.

## Key points
- A judge's ruling questioned the FDA's approval of the abortion pill, which was approved more than 20 years ago. (00:50)
- The Department of Justice and the drug's maker appealed, and an appeals court granted the appeal, so the drug remains on the market for now. (01:01)
- The judge's ruling is the first time courts have questioned the FDA's power to approve drugs, which is considered a big deal. (01:20)
- Congress gave the FDA powers to review drug safety and effectiveness based on scientific evidence, and health officials worry this authority could be undermined. (01:29)
- The FDA commissioner is most worried about the precedent this ruling could set for questioning FDA decisions on other drugs as well. (01:51)
- The FDA commissioner said her staff gave the abortion pill the same rigorous scientific review used for every other drug. (02:06)
- The speaker notes that Roe v. Wade has been overturned by the Supreme Court, and some states ban abortion while others continue to allow it. (02:44)
- The speaker says even experts do not know what happens next, and the case will show how much the FDA can rely on powers Congress gave it. (02:53)

## Chapters
- [00:00 to 00:50] Texas ruling and immediate reactions. Legal experts and medical professionals react to the Texas judge's ruling on the abortion pill and the uncertainty it creates.
- [00:50 to 01:20] Ruling details and appeal status. The ruling is explained, including the appeal that keeps the drug on the market while its legal status remains uncertain.
- [01:20 to 02:03] Concerns about FDA authority. The ruling is framed as the first court questioning of FDA drug approval powers, with worries about precedent for other drugs.
- [02:03 to 02:53] FDA commissioner's review and political context. The FDA commissioner describes the scientific review process and how the political climate has changed since the drug's approval.
- [02:53 to 03:17] Uncertainty about what comes next. Experts say the outcome of the case will determine how much the FDA's authority and drug decisions can be relied upon.

## Key quotes
- [01:20] interviewer: "The judge's ruling is the first time that the powers of the FDA to approve. Drugs has been questioned by the courts and that's a big deal."
- [01:51] interviewer: "And that's what she's most worried about."
- [02:06] interviewer: "she instructed her staff to give the drug the same rigorous scientific review process that"
- [02:44] interviewer: "We're Roe. V Wade has been overturned by the Supreme Court"
- [02:53] interviewer: "The situation means that even experts don't know what happens next"

## Questions this video answers
- What did the Texas judge order the FDA to do with mifepristone? [00:04]
- Is the abortion pill still available while the case is appealed? [01:01]
- Why is the judge's ruling considered a significant challenge to the FDA? [01:20]
- What precedent could this ruling set for other FDA drug decisions? [01:51]
- How did the FDA review the abortion pill when it was first approved? [02:06]
- What larger legal context affects how this case is viewed? [02:44]

## Content suitability
- health controversy [00:00-03:17]: The video discusses a contested court ruling on abortion medication and its legal status.
- politics [00:00-03:17]: Discussion centers on court rulings, federal agency authority, and the post-Roe legal landscape.


![Alice Park](https://static.time.com/v3/assets/bltea6093859af6183b/blt9b1ff6b12c3a4c3f/698a0b4397cdff3e366ba723/200116_Time_Headshots_Day552832-e1583529256299.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1:1)

by 

[Alice Park](https://time.com/author/alice-park/)


![Alice Park](https://static.time.com/v3/assets/bltea6093859af6183b/blt9b1ff6b12c3a4c3f/698a0b4397cdff3e366ba723/200116_Time_Headshots_Day552832-e1583529256299.jpg?branch=production&width=96&quality=75&auto=webp)

## Alice Park


Senior Correspondent

Apr 13, 2023 4:50 PM UTC

On April 7, 2023, Texas Judge Matthew J. Kacsmaryk ordered the Food and Drug Administration to invalidate its 23-year-old approval of mifepristone, one of the components of a medication abortion, a ruling that would effectively remove the drug from the market. Hours later, a Federal Judge in Washington state ordered the FDA to not make any changes to mifepristone’s current availability. Since then, a Federal Appeals Court has ruled that it can stay on the market, but imposed sharp restrictions for accessing it. 

![Alice Park](https://static.time.com/v3/assets/bltea6093859af6183b/blt9b1ff6b12c3a4c3f/698a0b4397cdff3e366ba723/200116_Time_Headshots_Day552832-e1583529256299.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1:1)

by 

[Alice Park](https://time.com/author/alice-park/)


![Alice Park](https://static.time.com/v3/assets/bltea6093859af6183b/blt9b1ff6b12c3a4c3f/698a0b4397cdff3e366ba723/200116_Time_Headshots_Day552832-e1583529256299.jpg?branch=production&width=96&quality=75&auto=webp)

## Alice Park


Senior Correspondent

Apr 13, 2023 4:50 PM UTC

When former U.S. Food and Drug Administration (FDA) commissioner Dr. Jane Henney approved the abortion pill mifepristone in 2000, she knew the decision was an important one for women’s health. It would also become incredibly contentious.

Henney, now 76, finds herself still defending that approval more than two decades later in 2023\. She talked to TIME on Apr. 12 about the unprecedented [legal decision](https://time.com/6270258/texas-abortion-pill-ruling-mifepristone/) to strip mifepristone of its FDA approval, and what it means for the future of the agency she once led. (This interview has been condensed and edited for clarity.)

### TIME: You were the first female commissioner of the FDA, from 1998 to 2001.

And the first commissioner to have a drug approval suspended. A lot of firsts; I’m not sure how that looks on a resume.

### How important was mifepristone to you when it came up for approval, given how it could impact women’s reproductive health?

I knew it was important. It came in as a first-in-class drug, so if approved would be the only anti-abortion drug on the market.

### Because it was the first drug of its kind to induce abortion, were there any special procedures the FDA followed during its review?

I knew it was important that we do this review in a pristine and thorough way and in a way that we could all stand confidently behind. I told the reviewers as they were going about their work, “You do this in a normal fashion, thoroughly and completely, and when you arrive at your conclusion—whether it’s an approval recommendation or a non-approval recommendation, or whether you need more information to make your recommendation—you’ll have my support.” The review process followed to the letter the normal way we reviewed new drugs.


**Read More**: [_What the New Abortion Pill Restrictions Mean—and What Comes Next_](https://time.com/6271557/new-abortion-pill-restrictions/)

I still feel the decision around approval was correct. And I am proud of it in that way. We did not let the political climate or political issues around abortion influence what the agency did.

### What was the political climate like at the time the drug was up for approval, and how does it compare to the highly contentious nature of abortion discussions today?

At that point, Roe v. Wade had been seen as lawful for nearly 30 years. It wasn’t like there wasn’t still tension around the issue of abortion…but we weren’t dealing with a climate where abortion was lawful in some \[states\] but not in others. In that sense, the situation has changed.

### Issues like abortion are so politically charged that a drug affecting termination of pregnancy will inevitably get caught up in that conflict. Was there pressure from parties with conflicting political interests who supported and opposed the drug?


Some call it political pressure, other people call it political interest, and it’s probably more heightened with a drug like mifepristone. These decisions the FDA is making affect real people, which is why the agency takes its role so seriously, and why it brings the best minds to the table with all kinds of expertise, from clinical to scientific to manufacturing and quality concerns.

**Read More**: [_What Happens Next in the Fight Over Abortion Pills_](https://time.com/6270733/abortion-pill-ruling-fda-explained/)

But they don’t use political measures in coming to their conclusions. They really have been entrusted, and expected, by statutory \[power\] to make such decisions. They hold that with great pride—and I think they should—the fact that they have been and are the gold standard for this drug approval process.

### How concerning is the fact that a judge can overturn a drug approval by the FDA?

Congress clearly signaled and has given FDA authority in this area because it has felt confident that the agency employs the kinds of scientific and disciplinary expertise to make many, many decisions around the approval of any drug in its review process. It both undermines the authority of the FDA if this decision stands, and makes it possible that this could happen to any other drug.


**Read More**: [_How the Abortion Pill Ruling Could Limit the FDA’s Authority_](https://time.com/6270389/abortion-pill-ruling-fda-authority/)

But it also goes a bit to the heart of the authority given and expected of the FDA in terms of its final decision-making authority with respect to drugs. Is it open to question? Then we would have an environment in which anything could be questioned. That would be terrifically disruptive to the marketplace and to the kind of confidence people can have in the products they take.

### Does the judge’s ruling to suspend approval of mifepristone undermine the FDA’s authority?

That is, in my view, one of more dangerous elements of this whole discussion right now. It can call into question all of this approval process. The direct conversations now are about mifepristone, but the bigger conversation is really about the credibility and authority—and the expectation by the public, through their legislature, that FDA will do the job it’s required to do.


### If you were leading the FDA now, how would you respond to this ruling, and how would you try to affirm the agency’s authority over drug approval?

It is a very hard question. I think everybody I know who has sat in the commissioner’s role, be it during a Republican or Democratic administration, was there because they are trying to do the best job they can for public health. But they have to do that within the constraints of the law. Sometimes your personal feelings come into conflict with some of those things, but you must do what you’re expected to do within the constraints of the law. How this is going play out—I think we are all waiting to see. It’s a very tough hot seat to be in right now.


## Transcript

[00:00] A ruling by a Texas judge has left the legal experts and medical
[00:04] professionals alike. Scrambling to understand what it means
[00:08] when the FDA approves a drug.
[00:10] And who, if anyone can question that decision,
[00:14] I just can't believe that the there is a person in Texas who
[00:20] thinks that they know more than the FDA in terms of what is a
[00:25] safe medication and to try and remove a medication that we've
[00:30] been using for abortions, miscarriage management and other
[00:33] things In Obstetrics and gynaecology for more than 20 years
[00:37] is
[00:39] Completely absurd much like the daps decision last summer.
[00:42] This news will and has already overwhelmed,
[00:45] confused and height and fear.
[00:46] Within the communities, we serve the judge ruled.
[00:50] That me. Also known as the abortion pill which was approved
[00:54] more than 20 years ago to induce abortion.
[00:57] In the first trimester should no longer be approved.
[01:01] The Department of Justice and the drugs maker have appealed
[01:05] the decision and an appeals court.
[01:06] Granted the appeal that means that for now,
[01:10] the drug remains on the market and doctors can prescribe
[01:13] it and patients can use it, but the legal status of the drug
[01:18] remains uncertain,
[01:20] The judge's ruling is the first time that the powers of the FDA
[01:25] to approve. Drugs has been questioned by the courts and that's
[01:29] a big deal.
[01:29] Congress. Gave the FDA powers to review Drug Assessment
[01:34] for safety and Effectiveness and make decisions about that based on
[01:39] scientific evidence and to have a judge questioned
[01:43] that decision and not process, could seriously undermine
[01:47] the fda's authority.
[01:48] And that's what health officials are most concerned about.
[01:51] I spoke to the commissioner of the FDA who approved me for Christmas.
[01:56] And that's what she's most worried about.
[01:58] Is the precedent that this could set for questioning
[02:01] the fda's decision or not.
[02:03] Just me for christone, but other drugs as well.
[02:06] And she said, she knew that.
[02:09] When this drug came up for approval,
[02:10] that it was very important for women's reproductive
[02:13] Health, she instructed her staff to give the drug the same rigorous
[02:17] scientific review process that
[02:20] Used for every other drug that it approved and that's despite
[02:24] the fact that as an abortion pill.
[02:26] And at the time, the very first abortion pill,
[02:29] there were political pressures.
[02:31] However she said even then Roe v Wade,
[02:35] had already been declared law and therefore it was lawful
[02:39] to have an abortion and the climate was not as contentious
[02:43] as it was today.
[02:44] We're Roe. V Wade has been overturned by the Supreme Court
[02:48] and some states ban abortion while other states continue
[02:52] to allow it.
[02:53] The situation means that even experts don't know what happens
[02:57] next and everyone's looking to this case,
[03:00] to better, understand how much it will undermine the fda's
[03:04] authority and how much the FDA can rely on the powers that Congress
[03:09] gave it to maintain that when it makes decisions about drugs,
[03:14] like the abortion pill, that those decisions should stand.

```json
[{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/6271082/jane-henney-interview/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/6271082/jane-henney-interview/"},"headline":"The FDA Commissioner Who Approved the Abortion Pill Is Still Fighting for It","datePublished":"2023-04-13T16:50:38.000Z","dateModified":"2026-10-19T07:15:11.044Z","description":"A Q&A with Dr. Jane Henney, who led the FDA when mifepristone was approved.","url":"https://time.com/6271082/jane-henney-interview/","keywords":["abortion","healthscienceclimate"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/bltdc6aa71c441fd514/698a3bf6cabb1d2119e514be/jane-henney-oath-fda.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Alice Park","jobTitle":"Senior Correspondent","url":"https://time.com/author/alice-park/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/bltdc6aa71c441fd514/698a3bf6cabb1d2119e514be/jane-henney-oath-fda.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"the oath of office of Commissioner of the Food and Drug Administration to Dr. Jane Henney","caption":"the oath of office of Commissioner of the Food and Drug Administration to Dr. Jane Henney","creditText":"Doug Mills/AP","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://time.com/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"https://time.com/tag/abortion/","name":"abortion"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/6271082/jane-henney-interview/","name":"The FDA Commissioner Who Approved the Abortion Pill Is Still Fighting for It"}}]},{"@context":"https://schema.org","@type":"VideoObject","name":"What Happens Next in the Fight Over Abortion Pills","description":"On April 7, 2023, Texas Judge Matthew J. Kacsmaryk ordered the Food and Drug Administration to invalidate its 23-year-old approval of mifepristone, one of the components of a medication abortion, a ruling that would effectively remove the drug from the market. Hours later, a Federal Judge in Washington state ordered the FDA to not make any changes to mifepristone’s current availability. Since then, a Federal Appeals Court has ruled that it can stay on the market, but imposed sharp restrictions for accessing it.","thumbnailUrl":"https://cdn.jwplayer.com/v2/media/YWU1AZq9/poster.jpg?width=720","uploadDate":"2023-04-14T16:55:19.000Z","contentUrl":"https://cdn.jwplayer.com/manifests/YWU1AZq9.m3u8","embedUrl":"https://time.com/6271082/jane-henney-interview/","duration":"PT3M17S","potentialAction":{"@type":"SeekToAction","target":"https://time.com/6271082/jane-henney-interview/?jw_start={seek_to_second_number}","startOffset-input":"required name=seek_to_second_number"}}]
```

